Fispemifene: Completed Phase IIb enrollment

Apricus completed enrollment of 161 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating 450 mg oral fispemifene once daily for 8 weeks. Apricus has exclusive, U.S. rights t...